A Phase 4 interventional study of Selective laser trabeculoplasty and Travoprost in Intraocular Pressure, sponsored by Prince of Songkla University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-08.
Sponsored by Prince of Songkla University · Phase 4, Interventional, and Treatment
The investigators conduct this study to access the effect of selective laser trabeculoplasty on 24-hour circadian tension curves of patients with open-angle glaucoma, normal tension glaucoma and ocular hypertension. This treatment effect is compared with that of the prostaglandin analogue, travoprost.
Selective laser trabeculoplasty is an effective treatment for lowering intraocular pressure in patients with open-angle glaucoma. Clinical evaluations of its effectiveness in individual patients usually are derived from baseline and post-laser measurements of intraocular pressure during office hours in the sitting position. Only a few studies have examined the efficacy of laser trabeculoplasty beyond office hours. Although the 24-hour effect of laser trabeculoplasty has been studied ,the study was conducted before the use of these new and more potent intraocular pressure lowering drugs. So it doesn't have any study to determine the effect of selective laser trabeculoplasty and travoprost to reduce the diurnal and nocturnal variation of Iintraocular pressure.
Prince of Songkla University is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Related to the severity of disease and visual acuity status
Related to surgical procedures
Treating with the selective laser trabeculoplasty
Device: Selective laser trabeculoplasty
Using eye drop: travoprost
Drug: Travoprost
Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
Also known as: The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
Also known as: Travatan benzalkonium-free
Change of circadian intraocular pressure
intraocular pressure values measured during daytime and nighttime, compare between selective laser trabeculoplasty and travoprost (include pre- and post-treatment intraocular pressure values)
Time frame: Six weeks after recieving treatment
Position related intraocular pressure
Intraocular pressure different when measuring in the sitting and supine position (include pre- and post-treatment intraocular pressure values
Time frame: Six weeks after the treatments
Ocular surface disease
Using the glaucoma symptom scale-10 (GSS-10) and ocular surface disease questionnaire for evaluation
Time frame: Six weeks after the treatments
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince of Songkla University